Journal of Hematology & Oncology

Table 5 Impact of prior murine antibody exposure and antidrug development on omburtamab pharmacokinetics

From: Phase 1 study of intraventricular ¹³¹I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

	No. of patients tested	CSF/blood ratio				t test
	No. of patients tested	Med	STDEV	Mean	SEM	t test
Dose 1
HAHA neg	16	22.3	32.9	36.3	2.1	0.04*
HAHA pos	11	54.2	239.3	162.6	21.8	0.04*
No prior Ab	17	19.8	22.9	25.5	1.4	0.02**
Prior Ab	14	55.9	213.1	144.6	15.2	0.02**
Dose 2
HAHA neg	19	20.4	20.3	25.0	1.1	0.04*
HAHA pos	10	28.1	99.9	76.9	2.8	0.04*
No prior Ab	15	14.9	15.0	19.9	1.0	0.05**
Prior Ab	14	33.7	85.5	65.4	2.4	0.05**

Med median, STDEV standard deviation from the mean, SEM standard error of the mean, HAHA human antihuman antigen, Ab antibody
^*t test comparing HAHA-negative vs HAHA-positive patients
^**t test comparing patients with prior mAb exposure vs those without

Back to article page

ISSN: 1756-8722

Contact us

General enquiries: journalsubmissions@springernature.com